Tuesday, July 17, 2018 8:33:18 AM
ZSAN - 4.14 Pre-market now at 4.40/4.53
Zosano Announces Positive Data from a Nonclinical Evaluation of Pharmacokinetics and Skin Tolerability Study for ADAM™ Technology for the Delivery of Zolmitriptan
Zosano Announces Positive Data from a Nonclinical Evaluation of Pharmacokinetics and Skin Tolerability Study for ADAM™ Technology for the Delivery of Zolmitriptan
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
